MP0712

MP0712 DLL3-targeting radiopharmaceutical (Lead-212 DOTAM-MAM279) · Molecular Partners AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MP0712, covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]

See pricing